Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity

Journal of Pathology

Volumn 222, Issue 4, 2010, Pages 400-409

  Willems, Stefan M ^a   Van Remoortere, Alexandra ^a   Van Zeijl, René ^a   Deelder, André M ^a   McDonnell, Liam A ^a   Hogendoorn, Pancras Cw ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clonal selection; Imaging mass spectrometry; Myxofibrosarcoma; Myxoid; Myxoid liposarcoma; Tumour progression

Indexed keywords

LIPID; PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; EXTRACELLULAR MATRIX; FEMALE; FIBROMYXOSARCOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIPID ANALYSIS; MALE; MASS SPECTROMETRY; MYXOSARCOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; SARCOMA; TISSUE SECTION; TISSUE SPECIFICITY; TUMOR CLASSIFICATION; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; DIAGNOSIS, DIFFERENTIAL; EXTRACELLULAR MATRIX; FEMALE; FIBROSARCOMA; HUMANS; LIPID METABOLISM; LIPOSARCOMA, MYXOID; MALE; MIDDLE AGED; NEOPLASM PROTEINS; SOFT TISSUE NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77957758578     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2771     Document Type: Article

References (58)

1. Graadt van Roggen JF, Hogendoorn PCW, Fletcher CDM,. Myxoid tumours of soft tissue. Histopathology 1999; 35: 291 - 312.
2. Willems SM, Wiweger M, Graadt van Roggen JF, et al., Running GAGs: myxoid matrix in tumor pathology revisited: what's in it for the pathologist? Virchows Arch 2010; 456: 181 - 192.
3. Willems SM, Schrage YM, Baelde JJ, et al., Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in composition. Histopathology 2008; 52: 465 - 474.
4. Willems SM, Mohseny AB, Balog C, et al., Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med 2009; 13: 1291 - 1301.
5. Willems SM, Debiec-Rychter M, Szuhai K, et al., Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol 2006; 19: 407 - 416.
6. Mentzel T, Calonje E, Wadden C, et al., Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 1996; 20: 391 - 405.
7. Campbell LL, Polyak K,. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 2007; 6: 2332 - 2338. (Pubitemid 350058682)
8. Gonzalez-Garcia I, Sole RV, Costa J,. Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci U S A 2002; 99: 13085 - 13089.
9. Konishi N, Hiasa Y, Matsuda H, et al., Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol 1995; 147: 1112 - 1122.
10. Maley CC, Galipeau PC, Finley JC, et al., Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature Genet 2006; 38: 468 - 473.
11. Marusyk A, Polyak K,. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010; 1805: 105 - 117.
12. Merlo LM, Pepper JW, Reid BJ, et al., Cancer as an evolutionary and ecological process. Nature Rev Cancer 2006; 6: 924 - 935.
13. Park SY, Gonen M, Kim HJ, et al., Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010; 120: 636 - 644.
14. Beerman H, Smit VT, Kluin PM, et al., Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. Cytometry 1991; 12: 147 - 154.
15. Bonsing BA, Corver WE, Fleuren GJ, et al., Allelotype analysis of flow-sorted breast cancer cells demonstrates genetically related diploid and aneuploid subpopulations in primary tumors and lymph node metastases. Genes Chromosomes Cancer 2000; 28: 173 - 183.
16. Mentzel T,. Biological continuum of benign, atypical, and malignant mesenchymal neoplasmsdoes it exist? J Pathol 2000; 190: 523 - 525.
17. Crozat A, Aman P, Mandahl N, et al., Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993; 363: 640 - 644.
18. Engstrom K, Willen H, Kabjorn-Gustafsson C, et al., The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells. Am J Pathol 2006; 168: 1642 - 1653.
19. Goransson M, Elias E, Stahlberg A, et al., Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. Int J Cancer 2005; 115: 556 - 560.
20. Riggi N, Cironi L, Provero P, et al., Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006; 66: 7016 - 7023.
21. Uranishi H, Tetsuka T, Yamashita M, et al., Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator. J Biol Chem 2001; 276: 13395 - 13401.
22. Zinszner H, Albalat R, Ron D,. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 1994; 8: 2513 - 2526.
23. Perez-Mancera PA, Bermejo-Rodriguez C, Sanchez-Martin M, et al., FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. PLoS One 2008; 3: e2569.
24. Tontonoz P, Spiegelman BM,. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008; 77: 289 - 312.
25. McDonnell LA, Heeren RM,. Imaging mass spectrometry. Mass Spectrom Rev 2007; 26: 606 - 643.
26. Cazares LH, Troyer D, Mendrinos S, et al., Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res 2009; 15: 5541 - 5551.
27. Djidja MC, Claude E, Snel MF, et al., Novel molecular tumour classification using MALDI-mass spectrometry imaging of tissue micro-array. Anal Bioanal Chem 2010; 397: 587 - 601.
28. Groseclose MR, Massion PP, Chaurand P, et al., High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 2008; 8: 3715 - 3724.
29. Kang S, Shim HS, Lee JS, et al., Molecular proteomics imaging of tumour interfaces by mass spectrometry. J Proteome Res 2010; 9: 1157 - 64.
30. McDonell LA, Corthals GL, Willems SM, et al., Peptide and protein imaging mass spectrometry in cancer research. J Proteomics DOI:10.1016/j.jprot.2010.05. 007.
31. Oppenheimer SR, Mi D, Sanders ME, et al., Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma. J Proteome Res 2010; 9: 2182 - 2190.
32. Antonescu C, Ladanyi M,. Myxoid liposarcoma. In World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Soft Tissue and Bone (2002 edn), Fletcher CDM, Unni KK, Mertens F, (eds). IARC Press: Lyon, 2004; 40 - 43.
33. Mentzel T, Van den Berg E, Molenaar WM,. Myxofibrosarcoma. In World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Soft Tissue and Bone (2002 edn), Fletcher CDM, Unni KK, Mertens F, (eds). IARC Press: Lyon, 2004; 102 - 103.
34. Guillou L, Coindre JM, Bonichon F, et al., Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15: 350 - 362.
35. Schwamborn K, Krieg RC, Reska M, et al., Identifying prostate carcinoma by MALDI-imaging. Int J Mol Med 2007; 20: 155 - 159.
36. McDonnell LA, van Remoortere A, van Zeijl RJ, et al., Mass spectrometry image correlation: quantifying colocalization. J Proteome Res 2008; 7: 3619 - 3627.
37. Norris JL, Cornett DS, Mobley JA, et al., Processing MALDI mass spectra to improve mass spectral direct tissue analysis. Int J Mass Spectrom 2007; 260: 212 - 221.
38. Deininger SO, Ebert MP, Futterer A, et al., MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers. J Proteome Res 2008; 7: 5230 - 5236.
39. Schwartz SA, Reyzer ML, Caprioli RM,. Direct tissue analysis using matrix-assisted laser desorption/ionization mass spectrometry: practical aspects of sample preparation. J Mass Spectrom 2003; 38: 699 - 708.
40. Caldwell RL, Holt GE, Caprioli RM,. Tissue profiling by mass spectrometry distinguishes clinical grades of soft tissue tumours. Cancer Genomics Proteom 2005; 2: 333 - 346.
41. Karas M, Bachmann D, Bahr U, et al., Matrix-assisted ultraviolet laser desorption of non-volatile compounds. Int J Mass Spectrom Ion Proc 1987; 78: 53 - 68.
42. Chaurand P, Sanders ME, Jensen RA, et al., Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am J Pathol 2004; 165: 1057 - 1068.
43. Cornett DS, Reyzer ML, Chaurand P, et al., MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nature Methods 2007; 4: 828 - 833.
44. Seeley EH, Caprioli RM,. Molecular imaging of proteins in tissues by mass spectrometry. Proc Natl Acad Sci U S A 2008; 105: 18126 - 18131.
45. Caldwell RL, Gonzalez A, Oppenheimer SR, et al., Molecular assessment of the tumor protein microenviroment using imaging mass spectrometry. Cancer Genomics Proteom 2006; 3: 279 - 288.
46. Francis P, Fernebro J, Eden P, et al., Intratumor versus intertumor heterogeneity in gene expression profiles of soft-tissue sarcomas. Genes Chromosomes Cancer 2005; 43: 302 - 308.
47. Orndal C, Rydholm A, Willen H, et al., Cytogenetic intratumor heterogeneity in soft tissue tumors. Cancer Genet Cytogenet 1994; 78: 127 - 137.
48. Prat E, Del RJ, Camps J, et al., Genomic imbalances in urothelial cancer: intratumor heterogeneity versus multifocality. Diagn Mol Pathol 2008; 17: 134 - 140.
49. Jovanovic L, Delahunt B, McIver B, et al., Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol 2008; 215: 145 - 154.
50. Guillou L, Aurias A,. Soft tissue sarcomas with complex genomic profiles. Virchows Arch 2010; 456: 201 - 217.
51. Singer S, Millis K, Souza K, et al., Correlation of lipid content and composition with liposarcoma histology and grade. Ann Surg Oncol 1997; 4: 557 - 563.
52. Millis K, Weybright P, Campbell N, et al., Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magn Reson Med 1999; 41: 257 - 267.
53. Chen JH, Enloe BM, Weybright P, et al., Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. Magn Reson Med 2002; 48: 602 - 610.
54. Bensinger SJ, Tontonoz P,. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008; 454: 470 - 477.
55. Willems SM, Schrage YM, Briaire-de Bruijn IH, et al., Kinome profiling of myxoid liposarcoma reveals NF-kB-pathway activity and casein kinase II inhibition as a potential treatment option. Mol Cancer 2010; 9: 257 DOI:10.1186/1476-4598-9-257 [Correction made here after initial online publication.].
56. Perez-Mancera PA, Vicente-Duenas C, Gonzalez-Herrero I, et al., Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development. Carcinogenesis 2007; 28: 2069 - 2073.
57. Grommes C, Landreth GE, Heneka MT,. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004; 5: 419 - 429.
58. Debrock G, Vanhentenrijk V, Sciot R, et al., A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89: 1409 - 1412.